Yun-Kun Qi

Prof. Dr. Yun-Kun Qi


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
XFXing-Yan Fu
Xing-Yan Fu
HYHao Yin
Hao Yin
XCXi-Tong Chen
Xi-Tong Chen
JYJing-Fang Yao
Jing-Fang Yao
YMYan-Nan Ma
Yan-Nan Ma
KWKewei Wang
Kewei Wang

6 July 2022 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
HYHao Yin
Hao Yin
XCXi-Tong Chen
Xi-Tong Chen
QCQiao-Na Chi
Qiao-Na Chi
YMYan-Nan Ma
Yan-Nan Ma
XFXing-Yan Fu
Xing-Yan Fu
KWKewei Wang
Kewei Wang

9 June 2023 in Bioorganic Chemistry
Verified
Journal Article
Closed access
HYHao Yin
Hao Yin
XFXing-Yan Fu
Xing-Yan Fu
HGHan-Yu Gao
Han-Yu Gao
YMYan-Nan Ma
Yan-Nan Ma
JYJing-Fang Yao
Jing-Fang Yao
KWKe-Wei Wang
Ke-Wei Wang

1 February 2017 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
Jun LiangJun Liang
Jun Liang
LZLin Zhang
Lin Zhang
XTXiang‐Long Tan
Xiang‐Long Tan
YQYun-Kun Qi
Yun-Kun Qi
SFShan Feng
Shan Feng
CTChang‐Lin Tian
Chang‐Lin Tian

3 January 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
HZHeng Zhang
Heng Zhang
JLJia-Jia Lin
Jia-Jia Lin
YXYa-Kai Xie
Ya-Kai Xie
XSXiu-Zu Song
Xiu-Zu Song
JSJia-Yi Sun
Jia-Yi Sun
FYFan Yang
Fan Yang
Transient receptor potential vanilloid 1 (TRPV1) ion channel is a classic analgesic target, but antagonists of TRPV1 failed in clinical trials due to their side effects like hyperthermia. Here we rationally engineer a peptide s-RhTx as a positive allosteric modulator (PAM) of TRPV1. Patch-clamp recordings demonstrate s-RhTx selectively potentiated TRPV1 activation. s-RhTx also slows down capsaicin-induced desensitization of TRPV1 in the presence of calcium to cause more calcium influx in TRPV1-expressing cells. In addition, our thermodynamic mutant cycle analysis shows that E652 in TRPV1 outer pore specifically interacts with R12 and K22 in s-RhTx. Furthermore, we demonstrate in vivo that s-RhTx exhibits long-lasting analgesic effects in noxious heat hyperalgesia and CFA-induced chronic inflammatory pain by promoting the reversible degeneration of intra-epidermal nerve fiber (IENF) expressing TRPV1 channels in mice, while their body temperature remains unaffected. Our results suggest s-RhTx is an analgesic agent as a PAM of TRPV1.

22 August 2025 in Materials Today Bio
Verified
Journal Article
Open access
YLYuying Liu
Yuying Liu
MZMan Zhao
Man Zhao
MZMeihua Zhang
Meihua Zhang
BYBin Yang
Bin Yang
YQYun-Kun Qi
Yun-Kun Qi
QFQinrui Fu
Qinrui Fu
Mesoporous silica nanoparticles (MSNs) have emerged as cornerstone biomaterials for nanomedicine due to their highly tunable physicochemical properties. This review highlights recent breakthroughs in MSN-based platforms for disease theranostics. We systematically outline fundamental synthesis strategies and detail how surface functionalization-imparting properties such as targeting, stimuli-responsiveness, and biomimicry-transforms MSNs from passive carriers into intelligent theranostic agents. The review then summarizes the major contributions of these engineered platforms across key diagnostic (e.g., advanced imaging) and therapeutic (e.g., targeted drug delivery, dynamic therapies) applications, underscoring their potential in tackling complex diseases. Finally, we address the critical challenges hindering clinical translation, including manufacturing scalability and long-term biocompatibility. We conclude by outlining future directions, such as integration with emerging modalities like immunotherapy, aimed at accelerating the bench-to-bedside transition of MSN-based nanomedicines.